Tag: Africa

Posted on

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

MIAMI, June 23, 2021 (GLOBE NEWSWIRE) — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15 million Series A financing. The financing was led by Santé Ventures who was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon. RapidPulse plans to use the proceeds to advance its RapidPulse™ Cyclic Aspiration System through expanded clinical evaluation and build out its platform of proprietary catheters.

The RapidPulse™ system was developed by Syntheon, a medical device incubator focused on developing next generation medical devices. Their various products, commercialized by the largest and most trusted medical device companies in the world, have treated over 50 million patients globally in applications ranging from laparoscopic surgery, cardiovascular, and flexible endoscopy. Syntheon has over 200 issued patents since its inception over 20 years ago.

“We are pleased to have partnered with an outstanding investor syndicate to move our RapidPulse™ technology forward in the clinic,” said Sean McBrayer, CEO of Syntheon who will also serve as initial CEO of RapidPulse. “Stroke is the second leading cause of death and the third leading cause of disability worldwide, and minutes matter in improving these outcomes. This investment will help us expand our clinical results and move towards regulatory approval in the United States.”

Joining the team are industry veterans Heather Harries and Cynthia Yang. Heather most recently served as General Manager for Terumo’s aortic business and will lead product development and operations for RapidPulse. Cynthia will lead clinical development for the company, after most recently working in the neurovascular division of Medtronic.

Dennis McWilliams, partner at Santé Ventures, added, “Heather and Cynthia bring exceptional domain expertise to the team at RapidPulse, and will complement the significant engineering development experience at Syntheon. RapidPulse is a disruptive platform opportunity in neurovascular, and has the potential to significantly improve patient outcomes for ischemic stroke patients.”

ABOUT RAPIDPULSE

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry. Visit www.rapidpulsemed.com for more information.

ABOUT SANTÉ VENTURES

Santé Ventures is a life sciences investment firm that invests in early-stage companies in medical device, biotechnology, and digitally enabled health services. We partner with entrepreneurs to build impactful companies, including Claret Medical (now part of Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), and Molecular Templates (NASDAQ: MTEM). Founded in 2006, Santé has just under $1 billion in assets under management, and has offices in Austin, TX and Boston, MA. For more information, please visit sante.com.

ABOUT EPIDAREX CAPITAL

Epidarex Capital is a transatlantic venture capital firm that builds exceptional life science companies in emerging hubs in the US and UK. Epidarex’s experienced team of early-stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in global healthcare. For more information, please visit www.epidarex.com

ABOUT HATTERAS VENTURE PARTNERS

Founded in 2000 and based in Durham, NC, Hatteras Venture Partners is a venture capital firm with a focus on seed and early stage healthcare investing. Through six funds and over $600 million under management, the firm has invested in breakthrough science and entrepreneurial grit in the areas of biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. To learn more, please visit www.hatterasvp.com.

ABOUT BROADVIEW VENTURES

Founded in 2008, Broadview Ventures is a mission-driven investment organization. Broadview’s primary goal is to improve human health in the areas of cardiovascular disease and stroke through investments in early stage companies developing innovative therapeutics, devices, and diagnostics. For more information about Broadview Ventures, visit broadviewventures.org.

MEDIA CONTACT:

Sean McBrayer, info@rapidpulsemed.com, 305-266-3388

Posted on

Conformis, Inc. Announces Exclusive Distribution Agreement in China

New Agreement expands Conformis’ global reach and brings patient-specific knee replacement systems to the largest market in the Asia-Pacific region

BILLERICA, Mass., June 23, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group (Hong Kong) Limited (XR Medical).

Under the distribution agreement, XR Medical will have exclusive rights for the sale, marketing, and distribution of Conformis’ patient-specific iTotal® CR & PS total knee replacement systems, iTotal® CR & PS patella devices, and iUni® and iDuo® partial knee replacement systems. Other products, such as Conformis’ recently approved Identity Imprint™ knee system and its hip portfolio of products, may be added in the future.

XR Medical’s sales team will provide sales and support exclusively to top-tier facilities in Hainan’s Boao Lecheng International Medical Tourism Pilot Zone (Pilot Zone) on behalf of Conformis. The region is a major center of medical tourism for dozens of countries.

“This distribution agreement is another example of progress as we execute our overall growth strategy. We are confident that our unique product portfolio will serve to accelerate Conformis’ international growth. And we are pleased to partner with XR Medical, which has an impressive track record of success in China,” said Mark Augusti, President and CEO of Conformis. “What is particularly attractive about XR Medical is its strong performance in the Pilot Zone. With access to patients visiting the region for treatment, this creates an opportunity to introduce a broad audience to the clinical benefits of Conformis technology. We believe that starting in the Pilot Zone positions us well and we anticipate that this relationship will serve as a model for future expansion opportunities in mainland China.”

The Pilot Zone is located on Hainan, a large island off China’s southern coast. It was established in 2019 to attract affluent Chinese citizens who might otherwise go abroad for their medical care. This region of China has developed top-level medical treatment facilities in a popular destination. Currently, medical tourists from dozens of countries, including those in Southeast Asia, are permitted to visit Hainan for a 30-day stay without visas.

The global market for knee joint reconstruction is projected at more than $9 billion. Of this total, the knee joint reconstruction market in the Asia-Pacific region is currently estimated to exceed $1.7 billion. Fortune Business Insights predicts a high growth rate for knee replacements in the region due to the combination of the increased prevalence of knee disorders, booming medical tourism, increased disposable incomes, and improved healthcare infrastructure.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and standard implants, along with single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Source: Conformis, Inc.

Media Contact:
Investor Relations
ir@conformis.com
(781) 374-5598
Posted on

Liquid Instruments Introduces Moku:Pro – A High Performance, Software-Defined Instrumentation Platform for Engineers and Scientists

New architecture delivers nine instruments with real-time measurement capabilities to the research lab

Moku:Pro In Lab Setting

Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.

CANBERRA, Australia and SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) — Liquid Instruments, an innovator in precision software-defined instrumentation, today announced Moku:Pro, a high-performance platform for engineering and research labs.

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Researchers in engineering and physics face constantly evolving requirements – with changes occurring on timescales much shorter than the lifespan of test equipment,” said Daniel Shaddock, CEO of Liquid Instruments. “Moku:Pro’s software-enabled-hardware architecture allows it to evolve as your applications evolve, something that is simply not possible with conventional test equipment.”

Moku:Pro hosts nine powerful instruments, including an oscilloscope, lock-in amplifier, PID controller, phasemeter, arbitrary waveform generator, data logger, spectrum analyzer, frequency response analyzer, and waveform generator to ensure researchers have the instrumentation they need to quickly characterize their set up and scale their experiments. The platform was designed to meet the needs of researchers in a variety of fields, from aerospace to semiconductor. Moku:Pro’s instrument suite is particularly suited to photonics applications, including spectroscopy, microscopy, metrology, gravitational wave detection, active laser stabilization, and quantum computing.

Moku:Pro

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Quantum computing pushes the performance limits of electronics, optics, and flexible real-time signal processing. We see software-defined instrumentation as the future of test and measurement systems for quantum computing,” said Andrew Horsley, CEO and Co-founder of Quantum Brilliance, a full-stack quantum computing company working on room temperature diamond technology.  “Moku:Pro is a workhorse of the lab and one of the most versatile photonics tools we’ve seen.”

Bringing Instrumentation Into the Modern Era
Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.  Advanced ADC blending technology ensures that each instrument can function with optimal sensitivity from RF to acoustic frequencies without compromising performance for flexibility. Full connectivity via Wi-Fi, Ethernet, and USB-C ensures industry-standard, hassle-free configuration.

A key benefit of software-defined instrumentation is that it gets better over time. Moku:Pro can receive over-the-air updates to deliver improved specifications, new instruments, or entirely new capabilities. Users can expect to see these benefits as soon as September when Liquid Instruments plans to release a feature that will give Moku:Pro the ability to run multiple instruments in conjunction with one another and hot-swap instruments in and out. In this multi-instrument mode, instruments can be combined and connected to form sophisticated signal-processing pipelines. Also slated for September release is a new cloud-based tool that will allow users to directly program Moku:Pro’s FPGA. With this capability, users can implement unique signal processing algorithms and create their own custom instruments, which will further widen the gap with conventional hardware.

Moku:Pro Specifications

  • 4 analog inputs and outputs
  • Blended ADC input (10-bit+18-bit) for low noise, high bandwidth applications
  • Sampling rate of 5 GSa/s (1 channel), 1.25 GSa/s (4 channels)
  • 9 integrated instruments, including a DC-600 MHz lock-in amplifier
  • 120 GB SSD for high-speed onboard storage
  • API support for Python and MATLAB
  • Starting at $12,000 for the base configuration, ranging up to $20,000 for the full suite.

A History of Success 
The Liquid Instruments technical leadership team brings deep expertise in complex measurements with experience from Australian National University, Max Planck Institute, Lockheed Martin, Caltech, and NASA’s Jet Propulsion Laboratory.  Moku:Pro expands the line of software-defined solutions from Moku:Lab, a twelve-instrument platform for research, and, more recently, Moku:Go, a complete and portable lab solution for undergraduate education.

For more information on Moku:Pro, visit: liquidinstruments.com

About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that students, engineers, and scientists learn, work, and discover. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. For more information, visit https://liquidinstruments.com.

The Project received funding from The Australian Government. Liquid Instruments gratefully acknowledges funding and support of the Australian Commonwealth Government through the CRC-P program administered by the Department of Industry Innovation and Science.

Media Contact
Codeword for Liquid Instruments
liquidinstruments@codewordagency.com
801-703-4092

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/37cb06a3-2242-4fe9-b6d2-0243a826051f

https://www.globenewswire.com/NewsRoom/AttachmentNg/8e84cd5f-7bf1-4276-9950-f57a12cfac19

Posted on

New architecture delivers nine instruments with real-time measurement capabilities to the research lab

Moku:Pro In Lab Setting

Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.

CANBERRA, Australia and SAN DIEGO, June 23, 2021 (GLOBE NEWSWIRE) — Liquid Instruments, an innovator in precision software-defined instrumentation, today announced Moku:Pro, a high-performance platform for engineering and research labs.

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Researchers in engineering and physics face constantly evolving requirements – with changes occurring on timescales much shorter than the lifespan of test equipment,” said Daniel Shaddock, CEO of Liquid Instruments. “Moku:Pro’s software-enabled-hardware architecture allows it to evolve as your applications evolve, something that is simply not possible with conventional test equipment.”

Moku:Pro hosts nine powerful instruments, including an oscilloscope, lock-in amplifier, PID controller, phasemeter, arbitrary waveform generator, data logger, spectrum analyzer, frequency response analyzer, and waveform generator to ensure researchers have the instrumentation they need to quickly characterize their set up and scale their experiments. The platform was designed to meet the needs of researchers in a variety of fields, from aerospace to semiconductor. Moku:Pro’s instrument suite is particularly suited to photonics applications, including spectroscopy, microscopy, metrology, gravitational wave detection, active laser stabilization, and quantum computing.

Moku:Pro

Moku:Pro accelerates the transition from traditional fixed-function test and measurement hardware to a flexible field-programmable gate array (FPGA)-based approach by making high-quality instruments accessible in an integrated, software-upgradeable platform.

“Quantum computing pushes the performance limits of electronics, optics, and flexible real-time signal processing. We see software-defined instrumentation as the future of test and measurement systems for quantum computing,” said Andrew Horsley, CEO and Co-founder of Quantum Brilliance, a full-stack quantum computing company working on room temperature diamond technology.  “Moku:Pro is a workhorse of the lab and one of the most versatile photonics tools we’ve seen.”

Bringing Instrumentation Into the Modern Era
Moku:Pro brings test and measurement into the modern age, allowing engineers and researchers to dynamically switch between instruments rather than needing multiple stand-alone devices.  Advanced ADC blending technology ensures that each instrument can function with optimal sensitivity from RF to acoustic frequencies without compromising performance for flexibility. Full connectivity via Wi-Fi, Ethernet, and USB-C ensures industry-standard, hassle-free configuration.

A key benefit of software-defined instrumentation is that it gets better over time. Moku:Pro can receive over-the-air updates to deliver improved specifications, new instruments, or entirely new capabilities. Users can expect to see these benefits as soon as September when Liquid Instruments plans to release a feature that will give Moku:Pro the ability to run multiple instruments in conjunction with one another and hot-swap instruments in and out. In this multi-instrument mode, instruments can be combined and connected to form sophisticated signal-processing pipelines. Also slated for September release is a new cloud-based tool that will allow users to directly program Moku:Pro’s FPGA. With this capability, users can implement unique signal processing algorithms and create their own custom instruments, which will further widen the gap with conventional hardware.

Moku:Pro Specifications

  • 4 analog inputs and outputs
  • Blended ADC input (10-bit+18-bit) for low noise, high bandwidth applications
  • Sampling rate of 5 GSa/s (1 channel), 1.25 GSa/s (4 channels)
  • 9 integrated instruments, including a DC-600 MHz lock-in amplifier
  • 120 GB SSD for high-speed onboard storage
  • API support for Python and MATLAB
  • Starting at $12,000 for the base configuration, ranging up to $20,000 for the full suite.

A History of Success 
The Liquid Instruments technical leadership team brings deep expertise in complex measurements with experience from Australian National University, Max Planck Institute, Lockheed Martin, Caltech, and NASA’s Jet Propulsion Laboratory.  Moku:Pro expands the line of software-defined solutions from Moku:Lab, a twelve-instrument platform for research, and, more recently, Moku:Go, a complete and portable lab solution for undergraduate education.

For more information on Moku:Pro, visit: liquidinstruments.com

About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that students, engineers, and scientists learn, work, and discover. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. For more information, visit https://liquidinstruments.com.

The Project received funding from The Australian Government. Liquid Instruments gratefully acknowledges funding and support of the Australian Commonwealth Government through the CRC-P program administered by the Department of Industry Innovation and Science.

Media Contact
Codeword for Liquid Instruments
liquidinstruments@codewordagency.com
801-703-4092

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/37cb06a3-2242-4fe9-b6d2-0243a826051f

https://www.globenewswire.com/NewsRoom/AttachmentNg/8e84cd5f-7bf1-4276-9950-f57a12cfac19

Posted on

Centrient Pharmaceuticals boosting statins API manufacturing capacity

Rotterdam, The Netherlands, June 21, 2021 (GLOBE NEWSWIRE) —

Summary:

  • Centrient Pharmaceuticals has started production at its newly built statins API manufacturing unit in Toansa, India.
  • With this expansion the company is doubling its production capacity of Atorvastatin and Rosuvastatin, meeting the increased demand for its high-quality uniquely produced statins.
  • Centrient Pharmaceuticals’ statins are one of the most sustainably produced in the industry by eliminating harmful solvents, generating less waste, and a reduced carbon footprint of 32% as compared to traditional manufacturers.
  • Using backward integrated manufacturing methods, and dedicated production facilities, Centrient Pharmaceuticals is able to offer its customers security of supply.

Centrient Pharmaceuticals (“Centrient”), the global leader in sustainable antibiotics, next-generation statins and anti-fungals, announced today to have started production at its new statins manufacturing unit. With the building of its second dedicated unit on the Toansa site in India now completed, the company will double its statins production capacity. This will enable Centrient to meet growing demand for its sustainably manufactured Atorvastatin and Rosuvastatin Active Pharmaceutical Ingredients (APIs).

Statins are currently the most prescribed drug class globally for the treatment of high cholesterol and cardiovascular diseases and are among the top-selling drugs worldwide. The markets for Atorvastatin and Rosuvastatin in particular, has shown steady growth in the past years, as a result of the continued global prevalence of high cholesterol issues, replacement of older generation statins, and genericization of the market.

Starting almost a decade ago, Centrient has grown today into one of the leading statin API suppliers worldwide, servicing large pharma companies around the globe.

Next to high-quality features like long shelf life and large batch sizes, the company offers security of supply to customers through its dedicated statins production facility and backward integration. Being backward integrated, Centrient is independent from external imports of starting materials. Its enzymatic route of synthesis and patented technology minimise the use of harmful solvents, generate less waste, and reduce the company’s carbon footprint by 32% as compared to traditional manufacturers.

The news of the facility expansion follows major milestones on statins that the company reached in the past years. In 2012, under the name of DSM Sinochem Pharmaceuticals, it was the first pharmaceutical manufacturer worldwide to offer generic Atorvastatin APIs under a Certificate of Suitability to the Monograph of the European Pharmacopoeia (CEP). Since 2014, it has produced the unique Atorvastatin APIs in its state-of-the-art facility in Toansa, India for third-party customers.

In addition, the company was one of the first three companies worldwide that started to offer generic Rosuvastatin APIs under CEP in 2016. Two years later, the first generic Rosuvastatin and Atorvastatin finished dosage forms were launched in Western Europe.

“With the doubling of our production capacity, we demonstrate our commitment to maintain our leadership position in line with our strategy and to continue supporting our customers’ business growth. Guided by our brand promise of Quality, Reliability, and Sustainability, Centrient’s Rosuvastatin and Atorvastatin offer superior performance in all three areas to the benefit of our customers and the environment.”, says Frans Vlaar, Chief Commercial Officer at Centrient.

Ground breaking of the new manufacturing unit started at the end of 2019 and commercial supplies from the new unit will start in mid-2021. With the new manufacturing line being operational and doubling the production capacity, Centrient will be even better positioned to secure supply, meeting the growing demand from customers and helping to improve the lives of patients who are in need of these medicine.

“We are extremely proud that we have been able to complete this project in a timely way given the challenges of executing such a complex project in the midst of the COVID pandemic,” says Jim McPherson, Chief Quality & Technical Operations Officer. “It reinforces our absolute commitment to meet the expectations of our customers as a partner of choice – delivering reliable and secure supply using leading sustainable technologies. The facility incorporates design features that allow further improvements in GMP and energy utilization, and enable greater automation for improved process control.”

———————————————————————————————————————————–


About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and antifungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.

We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2200 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-Mail: alice.beijersbergen@centrient.com.

Forward-looking statements
This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.

Alice Beijersbergen
Centrient Pharmaceuticals
alice.beijersbergen@centrient.com
Posted on

Janet D’Addario, Co-Founder of D’Addario & Co., and Former President of Providence House, Dies at 72.

Janet D’Addario

Photo provided by D’Addario & Company, Inc.

FARMINGDALE, N.Y., June 17, 2021 (GLOBE NEWSWIRE) — Janet D’Addario, a prodigious creative and philanthropic force throughout the world, and wife of D’Addario Chairman, Jim D’Addario, died on June 14th in her home, surrounded by her entire family. She was 72.

The cause was complications from gall bladder cancer, said her husband, Jim D’Addario.

Janet Marie D’Addario was born on December 10th, 1948 in Nassau County. Her education circumnavigated Long Island: St. Brigid in Westbury; St. Dominic’s High School in Oyster Bay, and Nassau Community College in Garden City.

In 1966, the course of her life would forever change when the 18-year-old lead singer of a folk group met another young, budding musician who was instantly smitten by her tender voice and magnetic personality. Jim and Janet D’Addario would go on to marry, sing and perform on stage together, and start an extraordinary 50-year partnership that produced a family, a philanthropic legacy, and the most prestigious music accessories business in the world.

When D’Addario & Co. was first founded in 1973, Janet used her creative talents to design the company’s advertising as well as the packaging design for all of their products. As a fledgling organization, Janet’s vision and compassion had a tremendous influence on the development of the culture that guides the organization today.

She would go on to wear many hats, including head of Artist Relations and co-founder of the D’Addario Foundation, which continues to provide music education to young children in underserved communities. Janet served as the Managing Director of the Foundation for 20 years—helping to raise awareness for the cause by producing classical music concerts in cities around the world.

Ms. D’Addario was known by family and friends for her peerless compassion and generosity—fervently believing that actions mean far more than just words. She would go on to serve 11 years on the Board of Long Island Cares, the charity created by Harry Chapin to eradicate hunger on Long island. As a devout Catholic, she supported numerous Catholic charities across the globe, the Long Island Catholic Hospital system as well as her own, personal parish, St. Brigid.

The one charity that held a particularly special place in her heart was Providence House, a New York institution that provides transitional housing for homeless women and children.

“Providence House is, in so many ways, the very embodiment of my wife…when she saw pain, she wanted to ease it. When she saw hunger, she brought food. When she saw homelessness, she provided shelter. But most importantly when Janet saw someone with no hope, she worked hard to provide them with the tools to restore their will to overcome the challenges they were facing.,” said Jim D’Addario.

Ms. D’Addario served as a Board Member of Providence House for 21 years and as its President from 2004-2019. Over those years, she helped raise millions of dollars to ensure thousands of women and children would have a pathway to a brighter future. Her invaluable work led to Janet and Jim being named the first People of Hope in 2002 and the construction of the 43-unit D’Addario Residence in Bedford Stuyvesant, Brooklyn.

In addition to her philanthropic work, Janet was an avid foodie and prolific painter. Not surprisingly, her greatest joy was bringing friends and family together for a homemade meal and the occasional musical performance by she and Jim, as well as their many musical friends.

Janet D’Addario was the daughter of Robert James Carbone and Annabelle (Eannaccone) Carbone of Westbury, New York. She is survived by her loving husband of over 50 years, Jim D’Addario, and their three children: Julie (Pat); Amy (Marcus) and Robert (Gina). She is also survived by eight grandchildren, and her beloved dogs, Dave and Blue.

In lieu of any gifts or flowers, the family is asking anyone wishing to pay their respects to consider a modest donation to Providence House (https://www.providencehouse.org/support-our-work).

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/88f5885b-1766-4876-89ab-810766a28ed6

Natalie Morrison
natalie.morrison@daddario.com